News

Details

Published: 02 July 2020

• portfolio-news

Immatics (NASDAQ: IMTX) today announced the completion of its business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Today, Immatics will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market. Proceeds from this transaction were approximately $253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors. 

Details

Published: 01 July 2020

• portfolio-news

MChE / F4 Pharma and SIRS therapeutics announce promising results from treatment of six severely ill COVID-19 patients with FX06 under “named patient use”. By time of start of FX06 administration, all patients were treated in the ICU with mechanical ventilation, and five - in addition - received extracorporeal membrane oxygenation (ECMO). Within a few days following the FX06 treatment, all patients showed an improvement of lung function parameters and a significant reduction of inflammation markers. 

Details

Published: 10 June 2020

• portfolio-news

Confo Therapeutics today announced the appointment of Rob Scott as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and development leadership in the global pharmaceutical and biotechnology industries, including his last position as Chief Medical Officer, Head of Development at AbbVie.